Managing menopause after breast cancer: Balancing risks and benefits

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 3, 2001, Pages 243-248

  Moore, Halle C F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; BELLADONNA ALKALOID; BELLERGAL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLONIDINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERGOTAMINE; ESTRADIOL; ESTROGEN; FLUOROURACIL; FLUOXETINE; LUBRICATING AGENT; MEGESTROL ACETATE; METHOTREXATE; PAROXETINE; PHENOBARBITAL; PHYTOESTROGEN; RALOXIFENE; SALCATONIN; TAMOXIFEN; TAMOXIFEN CITRATE; VENLAFAXINE; VITAMIN D;

AMENORRHEA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RECURRENCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG SAFETY; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; FEMALE FERTILITY; HOT FLUSH; HUMAN; MENOPAUSE; OSTEOPENIA; OSTEOPOROSIS; REPRODUCTIVE TOXICITY; REVIEW; RISK BENEFIT ANALYSIS; UROGENITAL TRACT DISEASE;

EID: 0035099275     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.3.243     Document Type: Review

References (37)

1. Swain S, Santen R, Burger H, et al. Treatment of estrogen deficiency symptoms in women surviving breast cancer [six-part series]. Oncology 1999; 13:109-136, 245-267, 397-432, 551-575, 721-735, 859-875.
2. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283:485-491.
3. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047-1059.
5. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339:1-15, 51-85.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer an overview of the randomised trials. Lancet 1998; 351:1451-1467.
7. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14:1718-1729.
8. Cobleigh MA, Bines J, Harris D, et al. Amenorrhea following adjuvant chemotherapy in breast cancer patients [abstract]. Proc ASCO 1995; 14:A158.
9. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of The International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34:632-640.
10. Bianco AR, Del Mastro L, Gallo C, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991; 63:799-803.
11. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Br Ca Res Treat 1997; 43:183-190.
12. Padmanabhan N, Howell A, Rubens RD. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986; 23:411-414.
13. Budman DR, Berry DA, Cirrincione CT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Nat Ca Inst 1998; 90:1205-1211.
14. Bonadonna G, Valagussa P, Zambetti M, Brambilla C. The Milan experience with adjuvant chemotherapy in premenopausal breast cancer. Rec Results Ca Res 1989; 115:113-117.
15. Collichio F, Pandya K. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival. Oncology 1994; 8:45-52.
16. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208.
17. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
18. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-461.
19. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA 1998; 280:605-613.
20. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127:973-980.
21. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17:1482-1487.
22. Brewster WR, Ziogas A, Anton-Culver H, et al. Breast cancer survival and hormone replacement therapy: a cohort analysis [abstract]. Proc Annual Meeting of the Society of Gynecologic Oncologists 2000.
23. Eastell RL. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736-746.
24. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16:2377-2381.
25. Loprinzi CL, Kugler JW, Sloan J, et al. Venlafaxine alleviates hot flashes: an NCCTG trial [abstract]. Proc ASCO 2000; 19:2a.
26. Stearns V, Isaacs C, Crawford J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes [abstract]. Br Ca Res Treat 1998; 50:308.
27. Loprinzi CL, Quella SK, Sloan JA, et al. Preliminary data from a randomized evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors [abstract]. Br Ca Res Treat 1999; 51:34.
28. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347-352.
29. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12:155-158.
30. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome: a double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol 1969; 33:795-799.
31. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91:6-11.
32. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000; 18:1068-1074.
33. Mandel FP, Geola FL, Meldrum DR, et al. Biologic effects of various doses of vaginally administered conjugated equine estrogens in post-menopausal women. J Clin Endocrinol Metab 1983; 57:133-139.
34. Deutsch S, Ossowski R, Benjamin I. Comparison between degree of systemic absorption of vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am J Obstet Gynecol 1981; 139:967-968.
35. Blumenfeld Z, Avivi I, Linn RE, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reproduction 1996; 11:1620-1626.
36. Collichio FA, Agnello R, Staltzer J. Pregnancy after breast cancer: from psychosocial issues through conception. Oncology 1998; 12:759-765.
37. Nicholson HS, Byrne J. Fertility and pregnancy after treatment for cancer during childhood or adolescence. Cancer 1993; 71(suppl):3392-3399.